Cefuroxime axetil induced glossitis: a case report

Asha Pathak, Achyut K. Pandey, Atul K. Mishra, Arun K. Mishra


Cefuroxime axetil is a semi synthetic cephalosporin antibiotic, which is prescribed for different types of infections such as lung, ear, throat, urinary tract, and skin. This is the drug of choice in the treatment and prevention of streptococcal infections. In this case, the patient was prescribed cefuroxime axetil, diclofenac, and paracetamol for pharyngitis. The patient developed glossitis 3 hrs after ingestion of above drugs which improved after withdrawing the offending drug. Glossitis is an uncommon, but serious adverse drug effect of cefuroxime axetil. It is important to recognize and manage it to prevent fatality. The case has been reported to the Pharmacovigilance Center Uttar Pradesh Rural Institute of Medical Sciences and Research Saifai, Etawah.


Adverse drug reaction, Glossitis, Pharyngitis, Pharmacovigilance center

Full Text:



Sullivan KM, Abraham G. Glossitis. In: Domino FJ, Baldor RA, Golding J, Grimes JA, Taylor JS, editors. 5-Minute Clinical Consult. 20th Edition. Philadelphia: Lippincott Williams & Wilkins; 2012.

Abdollahi M, Radfar M. A review of drug-induced oral reactions. J Contemp Dent Pract 2003;4(1):10-31.

Daily med current medication information. CEFTIN (cefuroxime axetil) powder, for suspension CEFTIN (cefuroxime axetil) tablet, film coated [GlaxoSmithKline LLC]. Available from: http://www.dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2f439b86-59d6-4350-aeb4-c904b3781db4. [Last accessed on 2014 May 03].

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD; 2011: 2109. Available from: http://www.toxnet.nlm.nih.gov/cgibin/sis/search/a?dbs+hsdb: @term+@DOCNO+7234. [Last accessed on 2014 May 03].

The Uppsala Monitoring Centre (the UMC), WHO Collaborating Centre for International Drug Monitoring Stora Torget 3, S-753-20 Uppsala, Sweden. Safety monitoring of medicinal products: Guidelines for setting up and running a pharmacovigilance centre. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/S.AfricaDraftGuidelines.pdf. [Last accessed on 2014 May 03].